How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

Burkert Pieske(German Centre for Cardiovascular Research), Carsten Tschöpe(German Centre for Cardiovascular Research), Rudolf A. de Boer(University Medical Center Groningen), Alan G. Fraser(Cardiff University), Stefan D. Anker(Universitätsmedizin Göttingen), Erwan Donal(Inserm), Frank Edelmann(German Centre for Cardiovascular Research), Michael Fu(Sahlgrenska University Hospital), Marco Guazzi(University of Milan), Carolyn S.P. Lam(University Medical Center Groningen), Patrizio Lancellotti(University of Liège), Vojtěch Melenovský(Institute of Clinical and Experimental Medicine), Daniel A. Morris(Charité - Universitätsmedizin Berlin), Eike Nagel(Goethe University Frankfurt), Elisabeth Pieske‐Kraigher(Charité - Universitätsmedizin Berlin), Piotr Ponikowski(Wroclaw Medical University), Scott D. Solomon(Brigham and Women's Hospital), Ramachandran S. Vasan(Boston University), Frans H. Rutten(Utrecht University), Adriaan A. Voors(University Medical Center Groningen), Frank Ruschitzka(University Hospital of Zurich), Walter J. Paulus(Amsterdam University Medical Centers), Petar Seferović(University of Belgrade), Gerasimos Filippatos(National and Kapodistrian University of Athens)
European Heart Journal
August 27, 2019
Cited by 1,766Open Access
Full Text

Abstract

Making a firm diagnosis of chronic heart failure with preserved ejection fraction (HFpEF) remains a challenge. We recommend a new stepwise diagnostic process, the 'HFA-PEFF diagnostic algorithm'. Step 1 (P=Pre-test assessment) is typically performed in the ambulatory setting and includes assessment for HF symptoms and signs, typical clinical demographics (obesity, hypertension, diabetes mellitus, elderly, atrial fibrillation), and diagnostic laboratory tests, electrocardiogram, and echocardiography. In the absence of overt non-cardiac causes of breathlessness, HFpEF can be suspected if there is a normal left ventricular ejection fraction, no significant heart valve disease or cardiac ischaemia, and at least one typical risk factor. Elevated natriuretic peptides support, but normal levels do not exclude a diagnosis of HFpEF. The second step (E: Echocardiography and Natriuretic Peptide Score) requires comprehensive echocardiography and is typically performed by a cardiologist. Measures include mitral annular early diastolic velocity (e'), left ventricular (LV) filling pressure estimated using E/e', left atrial volume index, LV mass index, LV relative wall thickness, tricuspid regurgitation velocity, LV global longitudinal systolic strain, and serum natriuretic peptide levels. Major (2 points) and Minor (1 point) criteria were defined from these measures. A score ≥5 points implies definite HFpEF; ≤1 point makes HFpEF unlikely. An intermediate score (2-4 points) implies diagnostic uncertainty, in which case Step 3 (F1: Functional testing) is recommended with echocardiographic or invasive haemodynamic exercise stress tests. Step 4 (F2: Final aetiology) is recommended to establish a possible specific cause of HFpEF or alternative explanations. Further research is needed for a better classification of HFpEF.


Related Papers

No related papers found

Powered by citation graph analysis